13F Holdings
中文EN

ACON Aclarion, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1635077 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY46.0%
TTM net income YoY-37.9%
TTM EPS YoY99.7%
Revenue 3-yr CAGR5.4%
Net income 3-yr CAGR—

Margins

Gross margin29.1%
Operating margin-10,789.2%
Net margin-10,260.0%
FCF margin—
EBITDA margin-10,662.3%

Returns

ROE-74.1%
ROA-69.7%
ROIC (approx.)-958.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio14.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$75,730$45,724$75,404$60,444$60,292
Cost of revenue$68,902$84,658$75,728$65,298$69,175
Gross profit$6,828-$38,934-$324-$4,854-$8,883
R&D expense$1.03M$888,766$873,336$1.07M$787,850
SG&A expense$4.12M$3.61M$3.25M$3.99M$1.83M
Operating income-$7.05M-$5.51M-$4.88M-$5.56M-$2.95M
Interest expense—$64,084$110,525$1.51M$474,911
Pretax income-$7.23M-$6.99M-$4.91M-$7.07M—
Income tax$0$0$0$0$0
Net income-$7.23M-$6.99M-$4.91M-$7.07M-$4.95M
EBITDA-$6.82M-$5.32M-$4.71M-$5.42M-$2.77M
EPS (basic)-13.61-7,478.90-79,782.00-19.61-6.58
EPS (diluted)-13.61-7,478.90-79,782.00-19.61-6.58
Weighted avg. shares (diluted)532,03694362381,598905,685
Banking
Deposits—$463,661———
Balance sheet
Cash & equivalents$12.02M$463,661$1.03M$1.48M$452,530
Receivables$29,680$18,326$13,270$18,569$6,280
Current assets$12.40M$824,279$1.29M$1.70M$732,204
PP&E, net$24,169$5,499$1,782$3,346$12,636
Intangibles$1.25M$1.29M$1.17M$1.21M$1.14M
Total assets$13.67M$2.12M$2.46M$2.91M$1.89M
Current liabilities$837,287$1.15M$3.19M$688,671$7.62M
Total liabilities$837,287$1.15M$3.19M$688,671$7.62M
Shareholders' equity$12.84M$970,057-$727,995$2.23M-$12.83M
Shares outstanding854,3711,370825,459491,345905,685
Cash flow statement
Operating cash flow-$7.16M-$5.27M-$3.65M-$4.95M-$2.40M
Capital expenditure$21,528$5,115$0——
Free cash flow-$7.19M-$5.28M-$3.65M——
Investing cash flow-$203,902-$321,937-$119,522-$207,870-$102,005
Financing cash flow$18.95M$5.03M$3.31M$6.19M$2.94M
Depreciation & amortization$227,406$193,139$162,670$143,622$186,388
Stock-based compensation$105,368$287,455$456,001$1.19M$177,489

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.